Unknown

Dataset Information

0

Erythroid-specific expression of beta-globin by the sleeping beauty transposon for Sickle cell disease.


ABSTRACT: Sickle cell disease (SCD) results predominately from a single monogenic mutation that affects thousands of individuals worldwide. Gene therapy approaches have focused on using viral vectors to transfer wild-type beta- or gamma-globin transgenes into hematopoietic stem cells for long-term expression of the recombinant globins. In this study, we investigated the use of a novel nonviral vector system, the Sleeping Beauty (SB) transposon (Tn) to insert a wild-type beta-globin expression cassette into the human genome for sustained expression of beta-globin. We initially constructed a beta-globin expression vector composed of the hybrid cytomegalovirus (CMV) enhancer chicken beta-actin promoter (CAGGS) and full-length beta-globin cDNA, as well as truncated forms lacking either the 3' or 3' and 5' untranslated regions (UTRs), to optimize expression of beta-globin. Beta-globin with its 5' UTR was efficiently expressed from its cDNA in K-562 cells induced with hemin. However, expression was constitutive and not erythroid-specific. We then constructed cis SB-Tn-beta-globin plasmids using a minimal beta-globin gene driven by hybrid promoter IHK (human ALAS2 intron 8 erythroid-specific enhancer, HS40 core element from human alphaLCR, ankyrin-1 promoter), IHbetap (human ALAS2 intron 8 erythroid-specific enhancer, HS40 core element from human alphaLCR, beta-globin promoter), or HS3betap (HS3 core element from human betaLCR, beta-globin promoter) to establish erythroid-specific expression of beta-globin. Stable genomic insertion of the minimal gene and expression of the beta-globin transgene for >5 months at a level comparable to that of the endogenous gamma-globin gene were achieved using a SB-Tn beta-globin cis construct. Interestingly, erythroid-specific expression of beta-globin driven by IHK was regulated primarily at the translational level, in contrast to post-transcriptional regulation in non-erythroid cells. The SB-Tn system is a promising nonviral vector for efficient genomic insertion conferring stable, persistent erythroid-specific expression of beta-globin.

SUBMITTER: Zhu J 

PROVIDER: S-EPMC3893920 | biostudies-other | 2007 Jun

REPOSITORIES: biostudies-other

altmetric image

Publications

Erythroid-specific expression of beta-globin by the sleeping beauty transposon for Sickle cell disease.

Zhu Jianhui J   Kren Betsy T BT   Park Chang Won CW   Bilgim Rasim R   Wong Phillip Y-P PY   Steer Clifford J CJ  

Biochemistry 20070518 23


Sickle cell disease (SCD) results predominately from a single monogenic mutation that affects thousands of individuals worldwide. Gene therapy approaches have focused on using viral vectors to transfer wild-type beta- or gamma-globin transgenes into hematopoietic stem cells for long-term expression of the recombinant globins. In this study, we investigated the use of a novel nonviral vector system, the Sleeping Beauty (SB) transposon (Tn) to insert a wild-type beta-globin expression cassette int  ...[more]

Similar Datasets

| S-EPMC3247234 | biostudies-other
| S-EPMC3972825 | biostudies-other
| S-EPMC5801840 | biostudies-literature
| S-EPMC3432063 | biostudies-literature
| S-EPMC3832362 | biostudies-literature
| S-EPMC7731152 | biostudies-literature
| S-EPMC4923320 | biostudies-literature
| S-EPMC6260868 | biostudies-other
| S-EPMC1557845 | biostudies-other
| S-EPMC4229213 | biostudies-literature